{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"67300","value":"11700"},{"groupId":"OG001","spread":"45000","value":"12400"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants who received carfilzomib 56 mg/m² on Cycle 1 day 8.","id":"OG000","title":"Carfilzomib 56 mg/m²"},{"description":"Participants who received carfilzomib 70 mg/m² on Cycle 1 day 8.","id":"OG001","title":"Carfilzomib 70 mg/m²"}],"paramType":"MEAN","populationDescription":"Participants who received at least 1 dose of study drug who had sufficient carfilzomib exposure and plasma concentration versus time data for the estimation of pharmacokinetic parameters by a non-compartmental analysis on day 8 of cycle 1.","reportingStatus":"POSTED","timeFrame":"Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion","title":"Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group","type":"SECONDARY","unitOfMeasure":"ng/mL"}